Im vergangenen Jahr erzielte Amphastar Pharmaceuticals Inc für sein leistungsstärkstes Segment, Other products, Einnahmen von 229.65M USD. Die Region United States leistete den größten Beitrag mit 681.42M USD im letzten Jahr. Im letzten Quartal berichtete Amphastar Pharmaceuticals Inc über Einnahmen in Höhe von 40.41M USD für den Zeitraum bis zum 2024-09-30, die aus dem leistungsstärksten Segment, BAQSIMI, stammten. United States trug mit 172.34M USD den höchsten Umsatz bei.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Other products

BAQSIMI

Primatene Mist

Epinephrine

Glucagon

Lidocaone

Other Revenues

Phytonadione

Enoxaparina

Naloxone

Other finished pharmaceutical products

Primatene® Mist

BAQSIMI NEB

Medroxyprogesterone

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Other products

229.65M(31.90%)

145.03M(19.81%)

--(--)

BAQSIMI

185.36M(25.75%)

126.90M(17.34%)

--(--)

Primatene Mist

108.67M(15.10%)

102.01M(13.94%)

89.32M(12.41%)

--(--)

Epinephrine

70.64M(9.81%)

94.09M(12.85%)

81.65M(11.35%)

74.20M(15.25%)

57.53M(13.71%)

23.80M(7.18%)

13.88M(4.60%)

Glucagon

69.08M(9.60%)

108.32M(14.80%)

113.68M(15.80%)

55.32M(11.37%)

47.64M(11.35%)

--(--)

Lidocaone

56.48M(7.85%)

55.85M(7.63%)

58.16M(8.08%)

52.54M(10.80%)

44.41M(10.59%)

41.11M(12.41%)

46.01M(15.24%)

Other Revenues

--(--)

19.15M(2.62%)

--(--)

Phytonadione

--(--)

43.17M(5.90%)

44.94M(6.25%)

49.50M(10.17%)

45.50M(10.84%)

42.65M(12.87%)

45.79M(15.16%)

Enoxaparina

--(--)

21.71M(2.97%)

31.53M(4.38%)

34.95M(7.18%)

35.96M(8.57%)

48.68M(14.69%)

42.70M(14.14%)

Naloxone

--(--)

15.73M(2.15%)

19.00M(2.64%)

26.27M(5.40%)

27.54M(6.56%)

33.42M(10.08%)

34.76M(11.51%)

Other finished pharmaceutical products

--(--)

140.82M(19.57%)

109.41M(22.49%)

87.88M(20.94%)

89.99M(27.16%)

72.94M(24.15%)

Primatene® Mist

--(--)

89.32M(12.41%)

84.31M(17.33%)

73.11M(17.43%)

51.73M(15.61%)

18.07M(5.98%)

BAQSIMI NEB

--(--)

51.16M(7.11%)

--(--)

Medroxyprogesterone

--(--)

27.85M(9.22%)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

United States

France

China

United Kingdom

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

681.42M(94.66%)

707.68M(96.68%)

635.19M(98.57%)

486.83M(97.56%)

419.87M(95.91%)

333.09M(95.21%)

304.90M(94.58%)

279.12M(94.72%)

France

35.28M(4.90%)

19.95M(2.73%)

4.70M(0.73%)

7.46M(1.49%)

11.88M(2.71%)

13.59M(3.89%)

15.98M(4.96%)

15.54M(5.28%)

China

3.18M(0.44%)

4.34M(0.59%)

4.50M(0.70%)

4.70M(0.94%)

6.02M(1.38%)

3.16M(0.90%)

1.48M(0.46%)

--(--)

United Kingdom

--(--)